The role of trephine bone marrow biopsies in the era of measurable residual disease<b>—</b>Results from the CLL10 trial of the German CLL Study Group (GCLLSG)-Reference-Cited by-同舟云学术

The role of trephine bone marrow biopsies in the era of measurable residual disease—Results from the CLL10 trial of the German CLL Study Group (GCLLSG)

Published:2024-07 Issue:7 Volume:8 Page:
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:HemaSphere

Author:

Kutsch Nadine¹^ORCID,Robrecht Sandra¹,Fink Anna¹,Lange Elisabeth²,Weide Rudolf³,Kiehl Michael G.⁴,Sökler Martin⁵⁶,Schlag Rudolf⁷,Vehling‐Kaiser Ursula⁸,Köchling Georg⁹,Plöger Christoph¹⁰,Gregor Michael¹¹,Plesner Torben¹²,Clausen Michael R.¹²,Oschlies Ilske¹³,Ritgen Matthias¹⁴,Herling Marco¹¹⁵,Fischer Kirsten¹,Döhner Hartmut¹⁶,Wendtner Clemens‐Martin¹⁷,Kreuzer Karl‐Anton¹,Stilgenbauer Stephan⁶¹⁵,Hallek Michael¹,Böttcher Sebastian¹⁸,Klapper Wolfram¹³^ORCID,Eichhorst Barbara¹

Affiliation:

1. Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group University of Cologne Cologne Germany

2. Department of Hematology and Oncology Evangelical Hospital Hamm Hamm Germany

3. Practice for Hematology and Oncology Koblenz Germany

4. Department of Internal Medicine Frankfurt (Oder) General Hospital Frankfurt/Oder Germany

5. Department II of Internal Medicine University Hospital Tübingen Tübingen Germany

6. Department of Hematology and Oncology Hospital STS AG Thun Thun Switzerland

7. Practice for Oncology Würzburg Germany

8. Oncology and Palliative Care, Dayclinic Landshut Landshut Germany

9. Private Oncology Practice Villingen‐Schwenningen Germany

10. Private Oncology Practice Mannheim Germany

11. Division of Hematology Cantonal Hospital of Lucerne Lucerne Switzerland

12. Department of Hematology and University of Southern Denmark Vejle Hospital Vejle Denmark

13. Hematopathology Section Christian‐Albrechts‐University Kiel Kiel Germany

14. Department II of Internal Medicine University of Schleswig‐Holstein Kiel Germany

15. Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology University Hospital Leipzig Leipzig Germany

16. Department III of Internal Medicine University Hospital of Ulm Ulm Germany

17. Department III of Internal Medicine University Hospital, LMU Munich Germany

18. Department III of Internal Medicine Medicine—Hematology/Oncology/Palliative Care Rostock University Medical Center Rostock Germany

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hem3.126

Reference14 articles.

1. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

2. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

3. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

4. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

5. EMA. Accessed April 8 2023. https://www.ema.europa.eu/en/documents/scientific-guideline/evaluation-anticancer-medicinal-products-man-appendix-4-condition-specific-guidance-revision-2_en.pdf